N- (9H- (2,7- dimethylfluoren- 9- ylmethoxy)carbonyl)leucine

04/01/1993 - "NPC 15669, an inhibitor of neutrophil recruitment, is efficacious in acetic acid-induced colitis in rats."
01/01/1993 - "The leukocyte recruitment inhibitor, NPC 15669 accelerates healing in acetic acid-induced colitis."
01/01/1993 - "The therapeutic efficacy of the leukocyte recruitment inhibitor, NPC 15669 (N-[9H-(2,7-dimethylfluoren-9-yl-methoxy)carbonyl]-L-leucine), was evaluated through the time course of acetic acid colitis in rats. "
04/01/1993 - "The efficacy of the leukocyte recruitment inhibitor, N-[9H-2,7-dimethylfluoren-9-ylmethoxy)carbonyl]-L-leucine (NPC 15669) was compared with drugs used to treat inflammatory bowel diseases in a rat model, acetic acid-induced colitis. "

04/01/1993 - "Intrarectal pretreatment with NPC 15669 results in a significant reduction of all measured indices of inflammation. "
05/25/1993 - "Effect of NPC 15669, an inhibitor of neutrophil recruitment and neutrophil-mediated inflammation, on neutrophil function in vitro."
07/15/1994 - "Finally, the leumedin NPC 15669, which had previously been shown to inhibit stimulated CD11b expression and neutrophil adherence to endothelial cells and to exhibit anti-inflammatory properties in various in vivo models of inflammation, inhibited the stimulation of tyrosine, phosphorylation induced by fMet-Leu-Phe. "
05/25/1993 - "The new anti-inflammatory agent N-[9H-(2,7-dimethylfluorenyl-9-methoxy)carbonyl]-L-leucine (NPC 15669) inhibits inflammation in several animal models dependent upon neutrophil activation and recruitment into the inflammatory lesion. "
03/01/1992 - "NPC 15669, a member of a new class of antiinflammatory agents termed leumedins, blocks inflammation in several animal models, including contact dermatitis and Arthus reaction, by inhibiting recruitment of neutrophils and lymphocytes into inflammatory lesions. "

11/01/1993 - "However, the mean myocardial infarct size was reduced by 51% with administration of NPC 15669 (30.7% +/- 6.8%) compared with controls (62.3% +/- 5.4%; p < 0.01). "
01/01/1995 - "We tested the efficacy of the novel leukocyte recruitment inhibitor NPC 15669 on myocardial stunning (MS) and preconditioned myocardial infarction (MI). "
01/01/1999 - "Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction."
11/01/1993 - "These data indicate that NPC 15669, an inhibitor of neutrophil adhesion, substantially reduces myocardial infarct size after transient left anterior descending artery occlusion and that adhesion of the white cell to vascular endothelium may be an important element of the pathogenesis of myocardial infarction."
11/01/1993 - "To determine if a simple inhibitor of neutrophil adhesion could reduce myocardial infarct size, we administered NPC 15669 (a new antiinflammatory agent that inhibits neutrophil adhesion) to 12 pigs (6 controls, 6 NPC-treated) in a porcine model of ischemia and reperfusion injury. "

11/01/1993 - "The efficacy of NPC 15669 on survival was associated with the reversal of leukopenia and a marked inhibition of neutrophil infiltration into the small intestine. "
07/09/1991 - "NPC 15669 enhances survival and reverses leukopenia in endotoxin-treated mice."
01/01/1993 - "In mice, ED50 doses of NPC 17761 (0.12 mg/kg) and NPC 15669 (4 mg/kg), administered together, increased survival (83%) and inhibited leukopenia (60% at 4 h) in response to a lethal dose of endotoxin. "

01/01/1995 - "We tested the efficacy of the novel leukocyte recruitment inhibitor NPC 15669 on myocardial stunning (MS) and preconditioned myocardial infarction (MI). "
01/01/1995 - "Effects of a Novel Leumedin NPC 15669 on Myocardial Stunning and Preconditioned Infarction Size in Swine."